Hims & Hers Wegovy Pill: Is the $49 Alternative Safe & Effective?

The telehealth company Hims & Hers Health has begun offering a lower-cost version of the Wegovy pill for weight loss, a move that could significantly reduce the financial barrier to accessing GLP-1 medications. However, the announcement has sparked concerns among obesity specialists and regulatory bodies regarding safety, efficacy and quality.

The new medication, described by Hims & Hers as a “compounded semaglutide pill,” starts at $49 per month for a five-month plan, increasing to $99 monthly thereafter. This is considerably less expensive than the directly-from-manufacturer Wegovy pill, currently priced at $149 per month for both the 1.5 milligram (mg) and 4 mg doses, with the 4 mg dose increasing to $199 per month after April 15, 2026.

For individuals struggling to afford GLP-1 medications due to limited or nonexistent insurance coverage, this price difference could be substantial. However, experts emphasize that cost is only one aspect of the equation.

Compounded Semaglutide Drugs Are Not FDA-Approved

Hims & Hers states that its compounded pill contains semaglutide, the same active ingredient found in injectable Wegovy and Ozempic, as well as the newly available Wegovy pill. Unlike those medications, compounded drugs – created by pharmacies to meet individual patient needs – are not approved by the FDA. This means the agency does not evaluate their safety, effectiveness, or quality.

While compounded drugs can fulfill an important medical need for certain patients, they also carry potential risks, according to the FDA. Hims & Hers asserts that its pill utilizes a “specialized formulation” designed to protect semaglutide during digestion and enhance absorption. The company also claims that compounded medications on its platform adhere to federal and state compounding standards, and that the active pharmaceutical ingredients are sourced from FDA-registered facilities.

Despite these assurances, experts stress that compounded drugs differ fundamentally from FDA-approved medications. “Compounded versions of semaglutide are not FDA-approved and are not required to undergo the rigorous clinical trials that approved medications must complete to demonstrate safety, efficacy, dosing accuracy, and manufacturing consistency,” explains Fatima Cody Stanford, MD, MPH, an obesity medicine specialist at Massachusetts General Hospital and Harvard Medical School.

Dr. Stanford does not prescribe or recommend compounded drugs for obesity treatment. Jorge Moreno, MD, an assistant professor and obesity medicine doctor at Yale Medicine, agrees. “Wegovy isn’t just a brand name — it’s an FDA-approved medication with a very specific, highly controlled formulation,” he says.

Will the Compounded Wegovy Pill Work the Same Way?

This remains a key unanswered question. Dr. Stanford points to the lack of robust clinical trial data demonstrating that compounded semaglutide formulations perform identically or have the same safety profile as FDA-approved versions. “Assuming equivalence without data is not scientifically sound or medically responsible,” she says.

Novo Nordisk has also publicly questioned whether a compounded pill can be properly absorbed. The company’s CEO reportedly stated that Novo’s Wegovy pill relies on a proprietary absorption technology that aids semaglutide survival through the digestive tract – a feature a copycat product would likely lack.

Hims & Hers disputes this claim, stating its compounded pill employs “liposomal technology that is intended to support absorption,” without providing further detail. The company has not released clinical trial data demonstrating comparable weight loss or semaglutide blood levels.

Dr. Moreno draws an analogy to baking: “The recipe and preparation have to be exact. Small changes in ingredients or technique can change the outcome, so something that looks similar may not behave the same way in the body.” He adds that Novo Nordisk holds a patent for the precise ingredients and formulation of the Wegovy pill. “These ingredients [in the compounded pill] were not tested in the clinical studies and could result in different efficacy and side effect profiles. I would not feel comfortable and would not advise using these medications,” he says.

Is the New Compounded Semaglutide Pill Safe?

Compounded medications are not inherently unsafe, but experts acknowledge they present more unknowns. “These products have not been tested in large, randomized clinical trials, may vary in strength or purity, and may not even contain the same active ingredient as FDA-approved semaglutide,” Dr. Stanford says. She also notes limited oversight of manufacturing and quality control.

This uncertainty is significant, as GLP-1 medications can cause side effects ranging from nausea and vomiting to serious complications. Without standardized data, it may be more challenging for clinicians to anticipate or manage problems.

Dr. Moreno also raises concerns about accountability. “What if patients develop unexpected side effects? Who will be responsible? Where will the patients be referred — their primary care provider, the emergency department? And what will we look for if we don’t know what side effects to expect?” he asks.

Does Expanding Access Justify the Risk?

Proponents of compounded GLP-1s argue that lower-cost options could address significant gaps in obesity care. Nearly half of U.S. Adults meet the criteria for obesity, yet access to FDA-approved medications remains uneven due to insurance exclusions and high out-of-pocket costs. “Prices will need to come down,” says Dr. Moreno.

Dr. Stanford acknowledges the access problem but believes lowering standards is not the solution. “Yes, this will expand access — but I believe the downside is too risky,” she says. “Obesity is a chronic disease that deserves evidence-based treatment. Lowering standards for safety and efficacy for people with obesity reinforces harmful inequities in care. Patients should not be asked to accept unproven therapies simply because effective, FDA-approved options are expensive or difficult to access,” she says.

Is the New Pill Legal?

U.S. Law permits compounding pharmacies to create customized medications under specific circumstances, such as when a patient requires a different dose or formulation than commercially available. However, large-scale marketing of compounded versions of brand-name drugs exists in a regulatory gray area.

According to reports, Novo Nordisk intends to pursue legal action against Hims & Hers, contending that mass compounding of a Wegovy pill copy is illegal and undermines the FDA’s drug-approval framework. The FDA issued a warning to Hims in September regarding its marketing of compounded semaglutide injections, stating that claims of containing “the same active ingredient as Ozempic and Wegovy” are misleading because compounded drugs are not FDA-approved.

Hims & Hers maintains compliance with federal and state compounding standards and asserts it has not compromised safety or efficacy. The legal dispute is ongoing, and regulators have not yet issued a ruling.

Should You Try the New Copycat Wegovy Pill?

Experts advise anyone considering compounded semaglutide to understand that it is not the same as FDA-approved Wegovy, even if it contains semaglutide.

“I don’t believe there is a truly ‘safe’ way to use compounded semaglutide for weight management, given the lack of clinical trial data and regulatory oversight,” Dr. Stanford says. She recommends using FDA-approved medications prescribed by clinicians trained in obesity medicine whenever possible.

Dr. Moreno adds that individuals who choose to try compounded options should remain under close medical supervision and promptly report any new symptoms, though he would not advise using these products himself. “As an obesity physician, my priority is always patient safety, so I would still evaluate and support a patient if concerns arise, regardless of where the medication came from,” he says.